**Abstract.** Background/Aim: To evaluate the association between TRIB1(rs6987702) and IL-9(rs1859430, rs2069870) genotypes with the development and manifestation of pituitary adenoma (PA). Materials and Methods: The study group included 141 patients with PA and the control group consisted of 287 healthy people. The genotyping of rs6987702, rs1859430 and rs2069870 was carried out using a real-time polymerase chain reaction. Results: Statistically significant results were obtained regarding the rs1859430, but there were no significant results regarding rs6987702. We found that the rs1859430 A/A genotype increased the odds of having recurrent PA six times (p=0.006) under the co-dominant model and four times (p=0.021) under the recessive model. Furthermore, the analysis showed that the G/A genotype increased the odds of having recurrent PA 2.3 times (p=0.003) under the co-dominant model, while G/A and A/A genotypes increased the odds 2.7 times (p=0.011) under the over-dominant model. Conclusion: Certain genotypes of rs1859430 can be associated with PA recurrence.

Pituitary adenoma (PA) is a benign pituitary gland tumor, which starts from the cells of adenohypophysis (1). PAs are mainly inactive, but certain types of PAs secrete hormones and become clinically apparent (2). They can also be classified according to their size: microadenomas, which are more commonly found in female and <60 years old patients, and macroadenomas, which are more prevalent in male and >60 years old patients (3-5).

TRIB1 is a protein, encoded by the TRIB1 gene, most commonly found in the nucleus of a cell. This protein belongs to a group of pseudokinases, which consist of 3 different domains: N-terminal PEST domain, pseudokinase domain and C-terminal COP1 binding peptide domain. TRIB kinases have unique sequences located at the C-terminal end (9). Tribbles-1 is mostly found in myeloid cells. It is thought to be important in intracellular signaling, and thereby, to participate in the management of cell cycle, differentiation, metabolism and proliferation, migration and invasion (9-11).

TRIB1 is thought to have oncogenic properties. Miyajima et al. (12) have found that TRIB1 inhibits the activity of the tumor suppressor protein p53 by disrupting its binding to the DNA and thereby promoting uncontrolled cell proliferation. The increased expression of the TRIB1 gene is associated with the etiology of breast, ovarian and thyroid cancer (9) and more aggressive form of hepatocellular carcinoma (13). Changes in the TRIB1 gene are associated with certain malignancies in the body. It is thought that TRIB1 gene amplification on chromosome 8 is associated with acute myeloid leukemia (10-11, 14-16).

IL-9 (formerly known as P40) is a 14 kDa glycoprotein composed of 144 amino acids (17). The gene encoding

---

**Correspondence to:** Mickevicius T, Lietuvos Sveikatos Mokslų Universitetas, LSMU, Eiveniu 2, 50161 Kaunas, Lithuania. Tel: +370 65785205, e-mail: tomas.mickevicius94@outlook.com

**Key Words:** Pituitary adenoma, TRIB1 rs6987702 gene polymorphism, IL-9 rs1859430, rs2069870 gene polymorphism, recurrence.

This article is freely accessible online.

**Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?**

TOMAS MICKEVICIUS¹, ALVITA VILKEVICIUTE², BRIGITA GLEBAUSKIENE², LORESA KRIAUCIUNIENE² and RASA LIUTKEVICIENE²

¹Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania;
²Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
human IL-9 is localized on chromosome 5q31-35 (18, 19). It is known that IL-9 can be secreted by Th1, Th2, Th17 and Th9 lymphocytes and Treg cells (18).

IL-9 production has been shown to be stimulated by TGF-β, IL-4 and IL-2 and inhibited by IFNγ (17). IL-9 is known to have a broad action potential and play an important role in the development of various autoimmune and inflammatory diseases (17, 20-24).

The role of IL-9 in oncology has been extensively studied. It has been shown that IL-9 contributes to the control of tumor growth (19, 25, 26). It is because this cytokine activates the production of CCL20, which into the foci of the tumor attracts CCR6+ dendritic cells and CCR6+ CD8 lymphocytes, which eradicate tumor cells. IL-9 enhances the cytotoxic effect of mastocytes, prolonging the action of dendritic cells (25, 26). Rivera Vargas et al. (26) have found that the IL-9 rs740002 polymorphism may be associated with an increased risk of melanoma.

Hence, some TRIB1 and IL-9 gene polymorphisms may play a role in the tumorigenesis of certain types of cancer. Therefore, in the present study, we investigated whether there is any relationship between the development and clinical manifestation of PA and the polymorphisms s6987702 in the TRIB1 gene and rs1859430, rs2069870 in the IL-9 gene.

Materials and Methods

Patients and selection. This study was carried out in the Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences and Laboratory of Ophthalmology, Neuroscience Institute, Lithuanian University of Health Sciences.

This study was approved by the Ethics Committee for Biomedical Research in Lithuanian University of Health Sciences (LUHS) (Number – BE-2/-13). All subjects provided written informed consent in accordance with the Declaration of Helsinki. The study was conducted in the Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences.

Based on our inclusion and exclusion criteria (27), two groups were formed in our study: PA group (n=141) and controls (n=287) (Figure 1).

Table I. Demographic characteristics.

| Characteristics | PA, N (%) | Control, N (%) | p-Value |
|-----------------|-----------|----------------|---------|
| Males, n (%)    | 54 (38.3) | 110 (38.3)     | 1.0     |
| Females, n (%)  | 87 (61.7) | 177 (61.7)     | 1.0     |
| Age, median (IQR) | 53.0 (22) | 52.0 (38)      | 0.165   |

PA: Pituitary adenoma; IQR: interquartile rate; p-Value: significance level.

Evaluation of PAs’ hormonal activity, invasiveness, recurrence and DNA extraction and genotyping. The evaluation of PA hormonal activity, invasiveness and recurrence has been described in detail previously (27). DNA extraction and genotyping were based on a real-time polymerase chain reaction (RT-PCR) method (28).

Statistical analysis. Deviation from Hardy-Weinberg equilibrium (HWE) of TRIB1 (rs6987702) and IL-9 (rs1859430, rs2069870) genotypes and alleles was evaluated using the Pearson’s χ² statistical test in the PA and control group.

All categorical variables of TRIB1 (rs6987702) and IL-9 (rs1859430) genotypes and alleles were expressed as absolute
numbers with percentages in brackets and compared using the Pearson’s $\chi^2$ and Fisher’s exact test (when $N$ is less than 50) in both groups. The age of study participants was presented as median and interquartile range (IQR). It was compared between both study groups using the nonparametric Mann-Whitney $U$-test. Binomial logistic regression analysis was performed as reported previously (29). Odds ratios (ORs) with 95% confidence intervals (CIs) were also presented. The lowest values of Akaike information criterion (AIC) showed the best genetic models. Statistically significant difference was indicated when $p<0.05$.

**Results**

The study group involved 141 patients with pituitary adenoma (PA): 54 males and 87 females. The median age of the study group was 53.0 years. The control group consisted of 287 subjects: 110 males and 177 females; the median age was 52.0 years ($p=0.165$) (Table I).

We performed additional statistical analysis considering the gender of study participants in the study and control groups. Unfortunately, the results did not reveal any associations between the rs6987702 and PA neither in males, nor in females.

Statistically significant results were found in the control group, while searching for the association between the rs6987702 and PA. The homozygote G/G genotype was more frequent in healthy males than in healthy females (70.0% vs 49.2%, respectively; $p=0.001$). The heterozygote G/A genotype was more frequent in healthy females than in healthy males (40.7% vs 25.5%, respectively; $p=0.011$) (Table II).

The A allele was also more frequent in healthy females than in healthy males (30.5% vs 17.3%; $p \leq 0.001$). However, the G allele was more frequent in healthy males than in healthy females (82.7% vs 69.5%; $p \leq 0.001$).

Binary logistic regression was performed to assess the impact of rs6987702, rs1859430 and gender on PA development, but the results did not show any significant difference.

PA: Pituitary adenoma; IL-9: Interleukin 9; p value: significance level; $^1p=0.001$; $^2p=0.011$; $^3p=0.001$.

### Table I. The frequency of genotypes and alleles of rs1859430 in patients with PA and control subjects, by gender.

| Genotype | Control group, N (%) | PA group, N (%) | p-Value |
|----------|----------------------|----------------|---------|
| G/G      | 77 (70.0)$^1$        | 38 (70.4)      | 1.0     |
| G/A      | 28 (25.5)$^2$        | 14 (29.5)      | 1.0     |
| A/A      | 5 (4.5)              | 2 (3.7)        | 1.0     |
| Allele   |                      |                |         |
| G        | 182 (82.7)$^3$       | 90 (83.3)      | 0.891   |
| A        | 38 (17.3)$^3$        | 18 (16.7)      |         |

**Table II. The frequency of genotypes and alleles of rs1859430 in patients with PA and control subjects, by gender.**

| IL-9 rs1859430 | Genotype | Males | p-Value | Females | p-Value |
|----------------|----------|-------|---------|---------|---------|
| Control group, N (%) | PA group, N (%) | Control group, N (%) | PA group, N (%) |
| G/G | 77 (70.0)$^1$ | 38 (70.4) | 1.0 | 87 (49.2)$^1$ | 52 (59.8) | 0.117 |
| G/A | 28 (25.5)$^2$ | 14 (29.5) | 1.0 | 72 (40.7)$^2$ | 32 (36.8) | 0.593 |
| A/A | 5 (4.5) | 2 (3.7) | 1.0 | 18 (10.2) | 3 (3.4) | 0.088 |
| Allele | | | | | | |
| G | 182 (82.7)$^3$ | 90 (83.3) | 0.891 | 246 (69.5)$^3$ | 136 (78.2) | 0.036 |
| A | 38 (17.3)$^3$ | 18 (16.7) | | 108 (30.5)$^3$ | 38 (21.8) | |

PA: Pituitary adenoma; IL-9: Interleukin 9; p value: significance level; $^1p=0.001$; $^2p=0.011$; $^3p=0.001$. 

The frequency of genotypes and alleles of rs6987702, rs1859430 and gender on PA development, but the results did not show any significant difference.

The frequency of genotypes and alleles of rs6987702 and rs1859430 in patients with PA and control subjects, by PA invasiveness. We also evaluated the impact of rs6987702 and rs1859430 on PA development and its invasiveness. Unfortunately, the results did not reveal any associations of the rs6987702 and rs1859430 with the invasiveness or non-invasiveness of PA.

Binary logistic regression was performed to assess the impact of rs6987702 and rs1859430 on PA invasiveness and non-invasiveness, but the results did not show any significant difference.

The frequency of genotypes and alleles of rs6987702 and rs1859430 in patients with PA and control subjects, by PA hormonal activity. The distribution of genotypes and alleles of rs6987702 and rs1859430 was evaluated in patients with PA, while considering the hormonal activity of the benign...
tumour of pituitary gland. Unfortunately, we did not find any associations between these two polymorphisms and hormonally active or inactive PA development.

Binary logistic regression was also performed in order to evaluate the impact of rs6987702 and rs1859430 on active PA and inactive PA development, but the results did not reveal any statistically significant association.

The frequency of genotypes and alleles of rs6987702 and rs1859430 in patients with PA and control subjects by PA recurrence.

| Polymorphism  | Genotype/ allele | PA without recurrence group, N (%) (n=111) | Control group, N (%) (n=287) | p-Value | PA with recurrence group, N (%) (n=30) | Control group, N (%) (n=287) | p-Value |
|---------------|------------------|------------------------------------------|----------------------------|---------|--------------------------------------|----------------------------|---------|
| TRIB1         | Genotype        |                                           |                            |         |                                      |                            |         |
| rs6987702     | T/T             | 58 (52.3)                                | 150 (52.3)                 | 0.998   | 15 (50)                              | 150 (52.3)                 | 0.85    |
|               | T/C             | 48 (43.2)                                | 110 (38.3)                 | 0.369   | 14 (46.7)                            | 110 (38.3)                 | 0.433   |
|               | C/C             | 5 (4.5)                                  | 27 (9.4)                   | 0.107   | 1 (3.3)                              | 27 (9.4)                   | 0.495   |
| Allele        | T               | 164 (73.9)                               | 410 (71.4)                 | 0.490   | 44 (70.3)                            | 410 (71.4)                 | 0.881   |
|               | C               | 58 (26.1)                                | 164 (28.6)                 |         | 16 (29.7)                            | 164 (28.6)                 |         |
| IL-9          | Genotype        |                                           |                            |         |                                      |                            |         |
| rs1859430     | G/G             | 78 (70.3)<sup>1</sup>                    | 185 (64.5)                 | 0.272   | 12 (40)<sup>1</sup>                  | 185 (64.5)                 | 0.010   |
|               | G/A             | 32 (28.8)                                | 92 (32.1)                  | 0.533   | 14 (46.7)                            | 92 (32.1)                  | 0.153   |
|               | A/A             | 1 (0.9)<sup>2</sup>                      | 10 (3.5)                   | 0.159   | 4 (13.3)<sup>2</sup>                 | 10 (3.5)                   | 0.034   |
| Allele        | G               | 188 (84.7)<sup>3</sup>                   | 462 (80.5)                 | 0.170   | 38 (63.3)<sup>3</sup>                | 462 (80.5)                 | 0.004   |
|               | A               | 34 (15.3)<sup>3</sup>                    | 112 (19.5)                 |         | 22 (36.7)<sup>3</sup>                | 112 (19.5)                 |         |

PA: Pituitary adenoma; IL-9: interleukin 9; p-value=significance level; <sup>1</sup>p=0.005; <sup>2</sup>p=0.007; <sup>3</sup>p=0.001.

Discussion

To our knowledge, *TRIB1* (rs6987702) and *IL-9* (rs1859430, rs2069870) gene polymorphisms association with pituitary adenoma was analysed for the first time. In our study, *IL-9* rs2069870 polymorphism deviated from Hardy-Weinberg equilibrium (<0.05) and thus was excluded from further analysis. We found that the *IL-9* rs1859430 was associated with PA development; unfortunately, we did not find any associations with the *TRIB1* (rs6987702) gene polymorphism. There are many others studies analyzing associations of the same gene polymorphisms with others types of tumours (30-37) and the oncogenic properties of TRIB1 have been shown in numerous studies (30-37). TRIB1 has been identified as an oncogene in acute myeloid leukemia (30), prostate cancer (31), colon and rectal cancer (32), gastric cancer (33), malignant mesothelioma (34), esophageal carcinoma (35), ovarian cancer (36), and thyroid cancer (37). Liang *et al.* (15) have suggested that 8q24 is significantly associated with human cancers and this region may carry oncogenes related to tumorigenesis and/or progression. TRIB1, which belongs to the Trib family, is classified as pseudokinase and has important roles in many cellular processes associated with tumors development.

Our analysis revealed that the G/G genotype and G allele of the *IL-9* (rs1859430) polymorphism are more prevalent among patients with a recurrent PA. Moreover, our results show the that A/A genotype and A allele are significantly more common among those patients, whom PA did not recur. We can hypothesize that IL9 can be important for PA recurrence but it has no impact on hormonal activity or invasiveness.

Besides the role of IL-9 in immune responses, its growth factor and antiapoptotic activities on multiple transformed cells suggest a potential role in hematological malignancies (38). Chruszcz *et al.* (39) have stated, that Interleukin 9...
facilitates an immunosuppressive environment to promote
tumor growth or to restrain tumor progression based on tumor
type. IL-9 also substantially contributes to the proliferation
and migration of lung cancer cells while helping them escape
apoptosis (40). Similar biological functions of IL-9 have been
also observed in breast cancer, colon carcinoma (39), and
hematopoietic malignancies (41). It is thought that IL-9 is
strongly associated with tumor progression; thus, blocking
IL-9 may be an applicable strategy for tumor treatment (42).
The IL-9 receptor is a member of the hematopoietic receptor
superfamily and is expressed in membrane-bound and soluble
forms (43). IL-9 in malignant tumors is almost exclusively
related to Hodgkin’s lymphoma and anaplastic large cell
lymphomas (44, 45). Also, the functional role of IL-9 has
been proven in experimental human and animal studies.
Hoelzinger et al. (39) results show the ability of IL-9 to
function as an inhibitor of adaptive immunity that prevents
the formation of immunologic memory to a growing tumor,
highlighting the potential for IL-9 neutralization as a unique
tool for cancer immunotherapy.

IL-9 is also known to be involved in mast cell differentiation
and T-cell lymphoma oncogenesis in mice (46). Notably, IL-9
overexpression induces thymic lymphomas in mice, and IL-9
production has an effect on Hodgkin’s disease and human T-
lymphotropic virus type I (HTLV-I)-transformed T cells in
humans. IL-9 activities also involve IL-2, -4, -7, -15 and -21
signaling, which is mediated by a specific receptor chain that
forms a heterodimeric receptor with the common γ chain (47).
The IL-9R and common γ chains associate with Janus kinase
(JAK) 1 and JAK3 and trigger the signal transducer and
activator of transcription (STAT)-1, -3 and -5, insulin receptor
signaling (IRS) and RAS-mitogen-activated protein kinase
(MAPK) pathways. In addition, IL-9 is not expressed by Th 2
and 9 cells in the absence of STAT6 expression. Dysregulated
IL-9 response also leads to autonomous cell growth and the
malignant transformation of lymphoid cells associated with
constitutive activation of the JAK/STAT pathway in vitro (48).

There are few limitations in this study. First, functional
studies were not performed in the present study in order to
confirm the association between the chosen SNPs and the

### Table IV. Binary logistic regression analysis of rs6987702 in control subjects and patients with PA with or without recurrence.

| Model     | Genotype | OR (95%CI) | p-Value | AIC  |
|-----------|----------|------------|---------|------|
| TRIB1     | rs6987702|            |         |      |
| PA without recurrence |          |            |         |      |
| Co-dominant | T/T       | 1          | 471.990 |      |
|            | T/C       | 1.129 (0.716-1.778) | 0.602  |      |
|            | C/C       | 0.479 (0.176-1.303)  | 0.150  |      |
| Dominant   | T/T       | 1          | 473.157 |      |
|            | T/C       | 1.001 (0.645-1.551)  | 0.998  |      |
|            | C/C       | 0.454 (0.170-1.211)  | 0.115  |      |
| Recessive  | T/T+C/C   | 1          | 470.262 |      |
|            | T/C       | 1.226 (0.786-1.912)  | 0.369  |      |
|            | C/C       | 0.885 (0.625-1.254)  | 0.493  | 472.683 |
| Over-dominant | T/T+C/C | 1 | 472.354 |      |
|            | T/C       | 1.273 (0.590-2.745)  | 0.539  |      |
|            | C/C       | 0.370 (0.047-2.921)  | 0.346  |      |
| Additive   | ---       | 0.858 (0.471-1.551)  | 0.108  | 470.262 |

| PA with recurrence |          |            |         |      |
| Co-dominant | T/T       | 1          | 200.589 |      |
|            | T/C       | 1.273 (0.590-2.745) | 0.539  |      |
|            | C/C       | 0.370 (0.047-2.921)  | 0.346  |      |
| Dominant   | T/T       | 1          | 200.473 |      |
|            | T/C       | 1.095 (0.516-2.323)  | 0.813  |      |
|            | C/C       | 0.332 (0.044-2.535)  | 0.288  |      |
| Recessive  | T/T+C/C   | 1          | 198.965 |      |
|            | T/C       | 1.408 (0.661-2.998)  | 0.375  |      |
|            | C/C       | 0.912 (0.506-1.645)  | 0.760  | 200.435 |
| Over-dominant | T/T+C/C | 1 | 199.749 |      |
|            | T/C       | 1.408 (0.661-2.998)  | 0.375  |      |
|            | C/C       | 0.912 (0.506-1.645)  | 0.760  |      |
| Additive   | ---       | 0.858 (0.471-1.551)  | 0.108  | 470.262 |

### Table V. Binary logistic regression analysis of rs1859430 in control subjects and patients with PA with or without recurrence.

| Model     | Genotype | OR (95%CI) | p-Value | AIC  |
|-----------|----------|------------|---------|------|
| IL-9      | rs1859430|            |         |      |
| PA without recurrence |          |            |         |      |
| Co-dominant | G/G      | 1          | 472.090 |      |
|            | G/A      | 0.825 (0.510-1.335) | 0.433  |      |
|            | A/A      | 0.237 (0.030-1.884)  | 0.174  |      |
| Dominant   | G/G      | 1          | 471.935 |      |
|            | G/A+A/A  | 0.767 (0.478-1.232)  | 0.273  |      |
|            | A/A      | 0.252 (0.032-1.991)  | 0.191  |      |
| Recessive  | G/G+A/A  | 1          | 470.711 |      |
|            | G/A      | 0.859 (0.531-1.387)  | 0.533  |      |
|            | A/A      | 0.737 (0.480-1.131)  | 0.163  | 471.139 |
| Over-dominant | G/G+A/A | 1 | 472.765 |      |
|            | G/A      | 0.859 (0.531-1.387)  | 0.533  |      |
|            | A/A      | 0.737 (0.480-1.131)  | 0.163  |      |
| Additive   | ---       | 0.859 (0.531-1.387)  | 0.533  |      |

| PA with recurrence |          |            |         |      |
| Co-dominant | G/G      | 1          | 193.911 |      |
|            | G/A      | 2.346 (1.043-5.277) | 0.039  |      |
|            | A/A      | 6.176 (1.684-22.387) | 0.006  |      |
| Dominant   | G/G      | 1          | 193.863 |      |
|            | G/A+A/A  | 2.721 (1.260-5.872)  | 0.011  |      |
|            | A/A      | 4.262 (1.249-14.540) | 0.021  |      |
| Recessive  | G/G+A/A  | 1          | 196.147 |      |
|            | G/A      | 4.262 (1.249-14.540) | 0.021  |      |
|            | A/A      | 4.262 (1.249-14.540) | 0.021  |      |
| Over-dominant | G/G+A/A | 1 | 198.038 |      |
|            | G/A      | 1.855 (0.868-3.961)  | 0.111  |      |
|            | A/A      | 2.435 (1.359-4.365)  | 0.003  | 191.928 |
| Additive   | ---       | 1.855 (0.868-3.961)  | 0.111  |      |

OR: Odds ratio; CI: confidence interval; AIC: Akaike information criterion; p: significance level.
development and clinical manifestation of PA. Second, the sample size of control subjects in our study was comparatively small. Despite these limitations, a thorough clinical examination of the patients can be considered as the strength of our study. Prior to our study, all the patients were consulted by a general practitioner, and patients with systemic infectious and noninfectious diseases, such as malignant tumors, rheumatoid diseases, and end-stage liver or renal diseases, were excluded from the study.

To conclude, a possible association between rs1859430 and the recurrence of PA has been found. However, additional studies are needed to support our findings.

Conflicts of Interest

None of the Authors have any conflict of interest regarding this study.

Authors’ Contributions

RL, LK and BG performed the Ophthalmological evaluation. TM and AV carried out the genotyping. TM performed the statistical analysis and drafted the manuscript. BG participated in the design of the study and RL conceived the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by the Lithuanian Science Council (Grant no. MIP-008/2014).

References

1 Fenstermaker R and Abad A: Imaging of pituitary and parasellar disorders. Continuum (Minneap Minn) 22: 1574-1594, 2016. PMID: 27740989. DOI: 10.1212/CON.0000000000000380

2 Oystese KA, Evang JA and Bollerslev J: Non-functioning pituitary adenomas: growth and aggressiveness. Endocrine 53: 28-34, 2016. PMID: 27066792. DOI: 10.1007/s12020-016-0940-7

3 Gruppetta M, Mercieca C and Vassallo J: Prevalence and natural history of incidental clinically non-functioning pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch Endocrinol Metab 60: 554-561, 2016. PMID: 27982201. DOI: 10.1590/2359-3997000000195

4 Day PF, Loto MG, Glerane M, Picasso MF, Lovazzano S and Giunta DH: Incidence and prevalence of clinically relevant pituitary adenomas: a population-based study in Malta. Pituitary 16: 545-553, 2013. PMID: 23239049. DOI: 10.1007/s11102-012-0454-0

5 Iglesias P, Arcano K, Trivino V, Garcia-Sanchez P, Diez JJ, Villabona C and Cordido F: Prevalence, clinical features, and natural history of incidentally clinically non-functioning pituitary adenomas. Horm Metab Res 49(9): 654-659, 2017. PMID: 28759937. DOI: 10.1055/s-0043-115645

6 Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C and Barnholtz-Sloan JS: CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Neuro Oncol 20: iv1-iv86, 2018. DOI: 10.1093/neuonc/noy131

7 Brain Tumor Registry of Japan (2005-2008). Neurol Med Chir 57(Suppl 1): 9-102, 2017. PMID: 28420810. DOI: 10.2176/nmc.sup.2017-0001

8 Roelfsema F, Biermasz NR and Pereira AM: Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1): 71-83, 2012. PMID: 21918830. DOI: 10.1007/s11102-011-0347-7

9 Eyers PA, Keeshan K and Kannan N: Tribbles in the 21st Century: The evolving roles of tribbles pseudokinases in biology and disease. Trends Cell Biol 27(4): 284-298, 2017. PMID: 27908682. DOI: 10.1016/j.tcb.2016.11.002

10 Lohan F and Keeshan K: The functionally diverse roles of tribbles. Biochem Soc Trans 41(4): 1096-1100, 2013. PMID: 23863185. DOI: 10.1042/BST20130105

11 Wang Y, Wu N, Pang B, Tong D, Sun D, Sun H, Zhang C, Sun W, Meng X, Bai J, Chen F, Geng J, Fu S and Jin Y: TRIB1 promotes colorectal cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways. Oncotarget 8(29): 47931-47942, 2017. PMID: 28624785. DOI: 10.18632/oncotarget.18201

12 Miyajima C, Inoue Y and Hayashi H: Pseudokinase tribbles 1 (TRB1) negatively regulates tumor-suppressor activity of p53 through p53 deacetylation. Biol Pharm Bull 38(4): 618-624, 2015. PMID: 25832642. DOI: 10.1248/bpb.b15-00003

13 Ye Y, Wang G, Wang G, Zhuang J, He S, Song Y, Ni J, Xia W and Wang J: The Oncogenic role of Tribbles 1 in hepatocellular carcinoma is mediated by a feedback loop involving microRNA-23a and p53. Front Physiol 8: 789, 2017. PMID: 29176948. DOI: 10.3389/physiol.2017.00789

14 Nakamura T: The role of Trib1 in myeloid leukemogenesis and differentiation. Biochem Soc Trans 43(5): 1104-1107, 2015. PMID: 26517931. DOI: 10.1042/BST20150110

15 Liang KL, Rishi L and Keeshan K: Tribbles in acute leukemia. Biol Pharm Bull 38(5): 1115, 2015. PMID: 26517933. DOI: 10.1042/BST20150117

16 Stein SJ, Mack EA, Rome KS and Pear WS: Tribbles in normal and malignant haematopoiesis. Biochem Soc Trans 43(5): 1112-1115, 2015. PMID: 26517933. DOI: 10.1042/BST20150117

17 Goswami R and Kaplan MH: A brief history of IL-9. J Immunol 186(6): 3283-3288, 2011. PMID: 21368237. DOI: 10.4049/jimmunol.1003049

18 Li H and Rostami A: IL-9: basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity. J Neuroimmune Pharmacol 5(2): 198-209, 2010. PMID: 20020328. DOI: 10.1007/s11481-009-9186-y

19 Lv X and Wang X: The role of interleukin-9 in lymphoma. Leuk Lymphoma 54(7): 1367-1372, 2013. PMID: 23127115. DOI: 10.3109/10428194.2012.745072

20 Ciccia F, Gugino G, Ferrante A, Cipriani P, Giacomelli R and Triolo G: Interleukin-9 and T helper type 9 cells in rheumatic diseases. Clin Exp Immunol 185(2): 125-132, 2016. PMID: 27159882. DOI: 10.1111/cei.12807

21 Koch S, Splen N and Finotto S: Th9 and other IL-9-producing cells in allergic asthma. Semin Immunopathol 49(9): 545-553, 2013. PMID: 23239049. DOI: 10.1007/s11481-009-9186-y

22 Weigmann B and Neurath MF: Th9 cells in inflammatory bowel diseases. Semin Immunopathol 39(1): 89-95, 2017. PMID: 27837255. DOI: 10.1007/s00281-016-0603-z
23 Clark RA and Schlapbach C: TH9 cells in skin disorders. Semin Immunopathol 39(1): 47-54, 2017. PMID: 27896634. DOI: 10.1007/s00281-016-0607-8

24 Elyaman W and Khoury SJ: Th9 cells in the pathogenesis of EAE and multiple sclerosis. Semin Immunopathol 39(1): 79-87, 2017. PMID: 27844107. DOI: 10.1007/s00281-016-0604-5

25 Vegran F, Apetoh L and Ghielmi F: Th9 cells: a novel CD4+ T-cell subset in the immune war against cancer. Cancer Res 75(3): 475-479, 2015. PMID: 25589348. DOI: 10.1158/0008-5472.CAN-14-2748

26 Rivera Vargas T, Humblin E, Vegran F, Ghielmi F and Apetoh L: TH9 cells in anti-tumor immunity. Semin Immunopathol 39(1): 39-46, 2017. PMID: 27832300. DOI: 10.1007/s00281-016-0599-4

27 Sidarate A, Liutkeviciene R, Glaubauskiene B, Vilkeviciute A and Kriauciuniene L: Transfer of estradiol protects aminotransferase (CETP) gene variants with pituitary adenoim. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2019. PMID: 31012439. DOI: 10.5507/bp.2019.016

28 Gedvilaita G, Vilkeviciute A, Kriauciuniene L, Asmoniene V and Liutkeviciene R: Does CETP rs5882, rs708272, SIRT1 rs12778365, FGR2 rs2981582, STAT3 rs744166, VEGFA rs833068, IL6 rs1800795 polymorphisms play a role in optic neuritis development? Ophthalmic Genet 40(3): 219-226, 2019. PMID: 31199170. DOI: 10.1080/13816810.2019.1622022

29 Liutkeviciene R, Vilkeviciute A, Morkunaite G, Glaubauskiene B and Kriauciuniene L: SIRT1 (rs12778365) role in pituitary tumorigenesis. Cancer Res 74(23): 6845-6855, 2014. DOI: 10.1158/0008-5472.CAN-14-0836

30 Jin G, Yamazaki Y, Takuma M, Takahara T, Kaneko K, Kuwata H, Iizuka N, Maruyama H and Ohbayashi C: Comparison of genomic abnormality in malignant mesothelioma by the site of carcinogenesis. Tumori 91(2): 175-179, 2005. PMID: 16171553.

31 Chen N and Wang X: Role of IL-9 and STAT1 in hematological malignancies (Review). Oncol Lett 7(3): 602-610, 2014. PMID: 24520283. DOI: 10.3892/ol.2013.1761

32 Hoelzinger DB, Dominguez AL, Cohen PA and Gendler SJ: Inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges. Cancer Res 74(23): 393-401, 2012. PMID: 23101182.

33 Knoops L and Renauld JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 10(10): 475-479, 2014. DOI: 10.1158/0008-5472.CAN-14-2748

34 Mez R, Houssiau FA, Herin M, Noel H, Mueller-Hermelink HK and Van Snick J: Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 109(9): 3998-4005, 2007. PMID: 17227832. DOI: 10.1182/blood-2006-08-041202

35 Chen N and Wang X: Role of IL-9 and STATs in hematological malignancies. Tumori 91(2): 175-179, 2005. PMID: 16171553.

36 George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, DeFazio A, Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G and Bowtell DD: Non-equivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res 19(13): 3474-3484, 2013. PMID: 23633455. DOI: 10.1158/1078-0432.CCR-13-0666

37 Puskas LG, Juhasz F, Zarva A, Hackler L Jr and Farid NR: Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand) 51(2): 177-186, 2005. PMID: 16171553.

38 Chen N and Wang X: Role of IL-9 and STATs in hematological malignancies (Review). Oncol Lett 7(3): 602-610, 2014. PMID: 24520283. DOI: 10.3892/ol.2013.1761

39 Hoelzinger DB, Dominguez AL, Cohen PA and Gendler SJ: Inhibition of adaptive immunity by IL-9 can be disrupted to achieve rapid T cell sensitization and rejection of progressive tumor challenges. Cancer Res 74(23): 393-401, 2012. PMID: 23101182.

40 Sordillo JE, Kelly R, Bunyavanich S, McGeachie M, Qiu W, Croteau-Chonka D, Soto-Quiros M, Avila L, Cledon JC, Brehm JM, Weiss ST, Gold DR and Litonjua AA: Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity. J Allergy Clin Immunol 134(6): 1622-1633, 2014. PMID: 25371304. DOI: 10.1016/j.jaci.2015.02.035

41 Custovic A and Simpson A: The role of inhalant allergens in allergic airways disease. J Investig Allergol Clin Immunol 22(6): 393-401, 2012. PMID: 23101182.

42 Merz H, Houssiau FA, Orscheschek K, Renaud JC, Fleiderer A, Herin M, Noel H, Mueller-Hermelink HK and Van Snick J: Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 109(9): 3998-4005, 2007. PMID: 17227832. DOI: 10.1182/blood-2006-08-041202

43 Knoops L and Renauld JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 10(10): 475-479, 2014. DOI: 10.1158/0008-5472.CAN-14-0836

44 Mez R, Houssiau FA, Herin M, Noel H, Mueller-Hermelink HK and Van Snick J: Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 109(9): 3998-4005, 2007. PMID: 17227832. DOI: 10.1182/blood-2006-08-041202

45 Chen N and Wang X: Role of IL-9 and STATs in hematological malignancies. Tumori 91(2): 175-179, 2005. PMID: 16171553.

46 Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PB, Sordillo JE, Kelly R, Bunyavanich S, McGeachie M, Liulite D, Croteau-Chonka D, Soto-Quiros M, Avila L, Cledon JC, Brehm JM, Weiss ST, Gold DR and Litonjua AA: Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity. J Allergy Clin Immunol 134(6): 1622-1633, 2014. PMID: 25371304. DOI: 10.1016/j.jaci.2015.02.035

47 Knoops L and Renaud JC: IL-9 and its receptor: from signal transduction to tumorigenesis. Growth Factors 22(4): 207-215, 2004. PMID: 15621723. DOI: 10.1080/08979710410001702879

48 Chen NA and Wang X: Role of IL-9 and STATs in hematological malignancies (Review). Oncol Lett 7(3): 602-610, 2014. PMID: 24520283. DOI: 10.3892/ol.2013.1761

Received May 10, 2020
Revised May 29, 2020
Accepted May 31, 2020